Treatment of Sjögren Syndrome with Oral Dryness and Mild Salivary Gland Dysfunction
In Sjögren syndrome, the degree of salivary gland impairment shapes the therapeutic approach to oral dryness. This protocol targets patients with mild glandular dysfunction — a subgroup where residual secretory capacity supports active stimulation strategies.
Clinical Scenario
Patients present with Sjögren syndrome and oral dryness in the setting of mild salivary gland dysfunction, defined by an unstimulated whole salivary flow of ≥0.1 mL/min — or an unstimulated flow below this threshold accompanied by a stimulated whole salivary flow above 0.7 mL/min. Because meaningful glandular reserve is preserved, non-pharmacological stimulation is the recommended first-line approach: gustatory stimulants such as sugar-free acidic candies, lozenges, or xylitol products, and mechanical stimulants such as sugar-free chewing gum.
When Additional Therapy Is Needed
For patients who are intolerant of or do not respond to standard approaches, the structured protocol includes rescue secretagogue therapy — a pharmacological option with an established safety record. The specific agents, selection criteria, and sequencing are defined in the complete protocol.
References
- In patients with mild glandular dysfunction, we recommend non-pharmacological glandular stimulation as the preferred first-line therapeutic approach, using gustatory stimulants (sugar-free acidic candies, lozenges, xylitol) and/or mechanical stimulants (sugar-free chewing gum) since, in these patients, glandular function can be stimulated.
- The preferred first therapeutic approach for oral dryness according to salivary gland function may be: Non-pharmacological stimulation for mild dysfunction; pharmacological stimulation for moderate dysfunction; saliva substitution for severe dysfunction.
- In patients who are intolerant or non-responders to muscarinic agents, some choleretic (anetholtrithione) or mucolytic (bromhexine, N-acetylcysteine) agents used as secretagogues in SjS since the 1980s may be considered as rescue therapies due to their good safety profile in the absence of alternative therapeutic options.
DOI: 10.1136/annrheumdis-2019-216114
View source ↗